WuXi Biologics
Offering End-to-End Solutions
Research Chemistry
Services
News
Translated from CHEManager’s report. Find the original German version here.
When the pharmaceutical and biotech industry gathers in Frankfurt for CPHI in October, discussions focus on key topics: increasing molecular complexity, rising regulatory demands, and the pressure to shorten development timelines. For WuXi AppTec, one thing is clear: integrated development and manufacturing approaches accelerate the path to patients. WuXi AppTec offers clients a seamless connection between research, development, and production.
In a recent interview with CHEManager, Dr. Ke Chen, Senior Vice President and Head of API Late Phase Development and Commercialization at WuXi AppTec, shares how WuXi AppTec is strengthening its presence in Europe and enabling global innovation through local excellence.
From Munich to Couvet and Beyond
A key part of this strategy is WuXi AppTec’s subsidiary Crelux in Munich, which has specialized in early drug discovery for nearly 20 years, focusing on structural biology, protein biochemistry, and biophysics. “In Munich, we provide the scientific depth needed to characterize target proteins and directly use structures for drug optimization,” explains Chen.
At the Swiss site in Couvet, WuXi AppTec works on late-stage development and commercial production. “The combination of Munich’s research and Switzerland’s manufacturing strength is a good example of our global network, which offers European clients access to comprehensive resources,” says Chen.
A Global Model – Locally Anchored
With around 6,000 active clients worldwide — from top 20 pharmaceutical companies to startups, biotechs, and research institutions — WuXi AppTec operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), integrating research, development, and production.
“CMC must not become a bottleneck in development,” says Chen. “Our goal is to ensure development steps run smoothly and projects advance efficiently and in compliance with regulatory requirements.”
This is especially crucial for young biotech companies. “Many biotech firms operate with small teams and limited budgets. We support them with project management experience and CMC expertise so they can advance their development goals faster and attract investors,” explains Chen. “WuXi AppTec provides tailored teams and flexible service packages precisely aligned with each project phase — from early development to clinical manufacturing and commercial production.”
Future Outlook
Chen sees the challenges of the coming years clearly: “We’re witnessing increasing molecular complexity — from chimeric molecules for targeted protein degradation (Proteolysis Targeting Chimeras, PROTACs) to peptides and oligonucleotides.”
WuXi AppTec is aligning its strategy accordingly. “We’re consistently expanding our expertise with advanced formulation and process solutions, and with teams that are well-versed in European regulatory requirements,” says Chen.
Europe remains a growth market for WuXi AppTec. “Here, excellent basic research, dynamic biotech companies, and investor interest come together. Our goal is to bring these innovations to the clinic and market approval faster — giving patients earlier access to new therapies.